Literature DB >> 10917538

Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?

P Price.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10917538      PMCID: PMC2374563          DOI: 10.1054/bjoc.2000.1342

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  2 in total

1.  Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model.

Authors:  Yumin Zhang; Melissa Saylor; Shenhua Wen; Matthew D Silva; Mark Rolfe; Joseph Bolen; Craig Muir; Corinne Reimer; Sudeep Chandra
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

2.  Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549.

Authors:  Seigo Ishino; Hiroshi Miyake; Patrick Vincent; Ikuo Mori
Journal:  Ann Nucl Med       Date:  2015-05-27       Impact factor: 2.668

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.